SEOUL, March 2 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market. Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie Inc. — is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. [...]
SEOUL, Feb. 24 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. on Thursday anticipated its antibody treatment against COVID-19 under development would show efficacy against the omicron variant. Celltrion said that CT-P63 has maintained strong neutralizing ability against the omicron variant during pseudo-virus testing. The candidate treatment is currently under clinical trials. The announcement [...]
SEOUL, Feb. 22 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Tuesday that a high-concentration version of its autoimmune disease biosimilar Yuflyma has won approval from European drug authorities. The European Medicines Agency (EMA) gave the green light to Celltrion’s application to sell Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie [...]
SEOUL, Feb. 16 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday that its net profit jumped 20.1 percent on-year last year on the back of robust sales of its biosimilar products in overseas markets. Net profit came to 623.7 billion won (US$521.1 million) last year on a consolidated basis, compared [...]
SEOUL, Feb. 14 (Korea Bizwire) — Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday. Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data. Remsima references Janssen [...]
SEOUL, Feb. 7 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its inhaled version of an antibody treatment candidate against COVID-19 has shown to be safe in a clinical trial. A total of 24 healthy volunteers were enrolled in a phase one clinical trial conducted by Celltrion’s global partner, Inhalon Biopharma, [...]
SEOUL, Jan. 14 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Friday its COVID-19 antibody treatment has won temporary approval from Swedish authorities. Swissmedic granted Temporary Authorization of Rekirona for adult COVID-19 patients who do not require supplementary oxygen treatment and are at high risk of developing into severe cases. The approval will [...]
SEOUL, Jan. 6 (Korea Bizwire) — South Korean biopharmaceutical company Celltrion Inc. said Thursday that its self-diagnostic kit for COVID-19 is available for purchase on global retailer Amazon. Celltrion DiaTrust COVID-19 Ag Home Test, co-developed by local health care business Humasis, received the U.S. Food and Drug Administration’s Emergency Use Authorization approval last year. The [...]
SEOUL, Jan. 3 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its antibody treatment candidate against COVID-19 has shown safety in its clinical trial. Celltrion said it has enrolled 24 healthy volunteers in its global phase one clinical trial and confirmed the safety, tolerability and pharmacokinetics of CT-P63. Separately, Celltrion said [...]
SEOUL, Dec. 30 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Thursday its new biosimilar of the arthritis drug Humira has won approval from Canadian authorities. Yuflyma, an adalimumab biosimilar with a high concentration, is used to treat patients with rheumatoid arthritis, psoriasis and inflammatory diseases. Yuflyma requires only half the solution administered [...]